SCHEMBL7243299

SCHEMBL7243299

CC(Oc1ccc(CC2SC(=O)NC2=O)cc1)c1nc2ccc(Cl)cc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 0.49
PPARG P37231 12/20 0.48
PPARA Q07869 3/20 0.45
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7248266 0.99 FFAR1 (0.48) FFAR1PPARGPPARAALDH1A1NPSR1
SCHEMBL1130792 0.90 PPARG (0.54) FFAR1PPARGPPARA
Hydrochloric Acid SCHEMBL6701459 0.89 PPARG (0.47) FFAR1PPARGPPARACYP3A4
Hydrochloric Acid SCHEMBL6064786 0.89 PPARG (0.53) FFAR1PPARGPPARACYP3A4
Hydrochloric Acid SCHEMBL4165069 0.89 PPARG (0.53) FFAR1PPARGPPARACYP3A4
SCHEMBL7243629 0.87 PPARG (0.44) FFAR1PPARGPPARAALDH1A1MEN1
SCHEMBL1130956 0.87 FFAR1 (0.54) FFAR1PPARGPPARAMEN1TP53
SCHEMBL6543635 0.86 PPARG (0.49) FFAR1PPARGPPARA
SCHEMBL6543694 0.86 PPARG (0.46) FFAR1PPARGPPARA
Hydrochloric Acid SCHEMBL7242467 0.86 PPARG (0.43) FFAR1PPARGPPARAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6569877-B2 Benzimidazolyl phenyl anticancer agents SANKYO COMPANY, LIMITED (JP) 2003-05-27 US claimed
US-20020137776-A1 Therapeutic and prophylactic agents for neoplasms SANKYO COMPANY, LIMITED (JP) 2002-09-26 US claimed
EP-1197211-A1 PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER Sankyo Company, Limited (JP) 2002-04-17 EP claimed
US-6569877-B2 Benzimidazolyl phenyl anticancer agents SANKYO COMPANY, LIMITED (JP) 2003-05-27 US disclosed
US-20020137776-A1 Therapeutic and prophylactic agents for neoplasms SANKYO COMPANY, LIMITED (JP) 2002-09-26 US disclosed
EP-1197211-A1 PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER Sankyo Company, Limited (JP) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137776-A1 Therapeutic and prophylactic agents for neoplasms VHL, TP53, BRCA1 FFAR1 4874/4885PPARG 1300/4885PPARA 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.